Valeant Pharma (VRX) Reports Unsurprising Results Ahead of Dec. Meeting - FBR Capital

October 20, 2014 2:58 PM

FBR Capital affirms Valeant Pharma (NYSE: VRX) at Outperform with a price target of $148 following Q3 results reported today.Analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found